A Phase 2/3 interventional study of Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma and Saline (NaCl 0,9 %) (placebo) in Arthritis Ankle and Arthritis Knee, sponsored by Integrant Pty Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Integrant Pty Ltd · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study will evaluate the efficacy and safety of intra-articular (IA) recombinant human growth hormone (rhGH; somatropin) combined with platelet-rich plasma (PRP) in adults with treatment-resistant knee and ankle osteoarthritis.
The study, sponsored by Integrant Pty Ltd and Prof. Reza Salleh as the primary investigator, is a Phase IIb, double-blind, randomised, placebo-controlled trial designed to determine whether IA rhGH and PRP can improve joint function and symptoms compared with saline placebo.
The study will recruit 192 participants, with separate knee and ankle cohorts. Participants will receive five IA injections, administered 7-16 days apart. The active treatment consists of 15 IU somatropin combined with 10 mL PRP per injection, while the control group will receive volume-matched sterile saline.
Outcomes will be assessed using WOMAC for knee participants and FAOS for ankle participants, with the primary endpoint assessed at 6 months after the final injection. Treatment success is defined as a ≥30% improvement from baseline in the relevant joint-specific score.
The study hypothesises that intra-articular rhGH combined with PRP will improve pain, symptoms and physical function in patients with treatment-resistant arthritis compared with saline placebo, potentially providing a non-surgical treatment option for these patients.
This clinical study will evaluate the efficacy and safety of intra-articular (IA) administration of recombinant human growth hormone (rhGH; somatropin) in combination with platelet-rich plasma (PRP) in adults with knee and ankle osteoarthritis resistant to conventional treatment. The investigational product will consist of 15 IU of somatropin combined with 10 mL of autologous PRP per injection.
The study, sponsored by Integrant Pty Ltd, will be conducted as a Phase IIb, multi-centre, double-blind, randomised, placebo-controlled, parallel-group superiority trial. Participants will be randomised 1:1 to receive either rhGH + PRP or volume-matched saline placebo. The primary site is St John of God Subiaco, with RegenU Clinics in Potts Point as the secondary site.
The study will recruit 192 participants, comprising 96 participants in the knee cohort and 96 participants in the ankle cohort. Within each cohort, 48 participants will receive rhGH + PRP and 48 will receive saline placebo. Participants will receive five IA injections into the affected knee or ankle joint, administered 7-16 days apart, over approximately 4-9 weeks. Injections will be performed under ultrasound guidance. Following each injection, participants in both treatment groups will undergo 20 minutes of non-invasive joint distraction.
Participants randomised to the placebo group will receive sterile normal saline (0.9% NaCl), volume-matched at approximately 10-12 mL per injection. To maintain the double-blind design, blood will also be collected from placebo participants for PRP preparation, but the blood will be discarded and the participant will receive saline only. Active and placebo preparations will be administered using identical opaque syringes and study-code labelling, with preparation performed by an independent unblinded clinical staff member. Participants, treating clinicians and outcome assessors will remain blinded to treatment allocation.
The inclusion criteria include ankle or knee arthritis resistant to treatment in the GP clinic setting; radiographically confirmed cartilage injury with Kellgren-Lawrence grade 0-3 demonstrated on MRI or weight-bearing X-ray within six months of study application; ability to provide informed consent; and ability to attend required follow-up visits. Exclusion criteria include known hypersensitivity to any component of the product; cancer diagnosis or suspicion; active or resected tumour; skeletal immaturity; pregnancy or breastfeeding; active infection at the injection site; open soft-tissue injury; specified metabolic disorders affecting the skeleton; age over 70 years; unstable or malaligned joint greater than 5 degrees; severe osteoarthritis classified as Kellgren-Lawrence grade 4, including bone-on-bone joints with no detectable cartilage; hypersensitivity to citrate or somatropin; inability to provide informed consent; or inability to attend required follow-up visits.
The primary endpoint is the proportion of participants achieving treatment success at six months, defined as a ≥30% improvement from baseline in the joint-specific functional score compared with the control group. FAOS will be used for participants with ankle osteoarthritis and WOMAC for participants with knee osteoarthritis. Secondary assessments include clinical assessment of symptoms and function at three months and six months, as well as repeat MRI and X-ray imaging at six months.
Blood samples will be collected for HGH measurement, including samples taken before and two hours after each injection following the baseline assessment. These measurements will be used to assess systemic exposure and the local versus systemic pharmacodynamic effects of the intervention. Safety will also be monitored through adverse-event assessment, laboratory testing and ongoing independent medical review.
The study hypothesises that intra-articular rhGH combined with PRP, administered within the standardised joint-distraction protocol, will improve clinical outcomes in patients with treatment-resistant knee or ankle osteoarthritis compared with saline placebo. The study is intended to provide preliminary evidence of efficacy and safety and inform the design of a subsequent Phase III clinical trial.
This is the only study on the registry with Integrant Pty Ltd as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria include:
Exclusion Criteria:
Known for ARTG registered somatropin from various manufacturers (Humatrope, Genotropin) have been used to guide the development of somatropin-related exclusion criteria.
Exclusion criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection of 15 iu of Somatropin and 10ml of Platelet-Rich Plasma conjunct via intra-articular injection of the arthritic ankle. This will be administered with a 7-16 day buffer period between each injection. There will be five total injections for the study.
Drug: Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma
Injection of 15 iu of Somatropin and 10ml of Platelet-Rich Plasma conjunct via intra-articular injection of the arthritic knee. This will be administered with a 7-16 day buffer period between each injection. There will be five total injections for the study.
Drug: Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma
Injection of sterile saline, volume matched to the active treatment (10ml-12ml) intra-articular injection of the arthritic knee. This will be administered with a 7-16 day buffer period between each injection. There will be five total injections for the study.
Drug: Saline (NaCl 0,9 %) (placebo)
Injection of sterile saline, volume matched to the active treatment (10ml-12ml) intra-articular injection of the arthritic ankle. This will be administered with a 7-16 day buffer period between each injection. There will be five total injections for the study.
Drug: Saline (NaCl 0,9 %) (placebo)
Intervention will be an intra-articular injection of 15 units of HGH and 10 mL PRP conjunct. Five total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.
To enable a double-blind 1:1 randomised controlled design, the control arm will receive intra-articular sterile saline (0.9% sodium chloride) as placebo. Normal saline is the standard placebo used in many intra-articular injection trials for osteoarthritis. It can be easily matched for volume (\~10-12 mL) and appearance (using identical opaque syringes and study codes) to maintain effective blinding for participants, injecting physicians, and outcome assessors.
Ankle mobility and functionality test with FAOS scale
The Foot and Ankle Outcome Score (FAOS) scale is a widely used outcome measure for ankle and hindfoot conditions, including ankle arthritis, assessing pain, function, and alignment, with scores ranging from 0 to 100, where higher scores indicate better function.
Time frame: Baseline, 6-months after final injection
Knee mobility and functionality test with WOMAC scale
The Western Ontario and McMaster Universities Arthritic Index (WOMAC) is a validated self-administered health status measure used in assessing pain, stiffness, and function in patients with arthritic knee. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation, with the score range being 0-68. A higher score indicates worse symptons.
Time frame: Baseline, 6-months after final injection
MRI Imaging of the affected arthritic joint
The MRI scans will be evaluated by a radiologist blinded to the treatment allocation to assess changes in: Cartilage volume and thickness, Synovial inflammation (e.g., synovitis), Bone marrow edema, Osteophyte formation, Other structural changes relevant to arthritis progression
Time frame: Baseline, 6-months after final injection
Blood test for hormone
Blood tests to check for growth hormone within the blood system.
Time frame: Baseline, 2 hours after each injection
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.